Evidence

BROWSE BY STUDY TYPE OR CONFERENCE
All
  • All
  • MODEL VALIDATION
  • CLINICAL VALIDATION
  • AACR
  • ASCO
  • ASH
BROWSE BY YEAR
All
  • All
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • Archive
Computational Omics Biology Model (CBM) Identifies Amplifications of Chromosome 6p to Predict Chemotherapy Resistance

Journal of Thoracic Oncology,

Computational Omics Biology Model (CBM) Identifies Novel Biomarkers to Inform Combination Platinum Compound Therapy in NSCLC

Journal of Thoracic Oncology,

Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type

Oncotarget,

Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit

Journal of Neuro-Oncology ,

Superior overall survival (OS) and disease-free survival (DFS) predictions for patients with glioblastoma multiforme (GBM) using Cellworks Singula: myCare-022-03.

ASCO Meeting Library,

Superior overall survival (OS), progression-free survival (PFS), and clinical response (CR) predictions for patients with non-small cell lung cancer (NSCLC) using Cellworks Singula: myCare-022-05.

ASCO Meeting Library,

Cellworks Omics Biology Model (CBM) to predict therapy response and identify biomarkers for all-trans retinoic acid (ATRA) benefit as addition to induction chemotherapy in adults with acute myeloid leukemia (AML).

ASCO Meeting Library,

Cellworks Omics Biology Model (CBM) to identify amplifications of chromosome 11p and 1p predict paclitaxel and carboplatin resistance.

ASCO Meeting Library,

STAY INFORMED

Top